Novo Nordisk A/S (NVO) Earnings History
Elite Compounder36 years of earnings data (1990–2025) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality
Loading earnings history...
Novo Nordisk A/S (NVO) Earnings Overview
As of June 21, 2026, Novo Nordisk A/S (NVO) reported trailing twelve-month net income of $121.96B, reflecting +1.8% year-over-year growth. The company earned $27.41 per diluted share over the past four quarters, with a net profit margin of 33.1%.
Looking at the long-term picture, NVO's 5-year EPS compound annual growth rate (CAGR) stands at +20.6%, indicating exceptional earnings growth. The company achieved its highest annual net income of $102.43B in fiscal 2025, representing a new all-time high.
Novo Nordisk A/S maintains industry-leading profitability with a gross margin of 81.0%, operating margin of 41.3%, and net margin of 33.1%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including LLY ($25.27B net income, 31.7% margin), SNY ($7.81B net income, 16.7% margin), AZN ($10.39B net income, 17.5% margin), NVO has outperformed on profitability metrics. Compare NVO vs LLY →
NVO Earnings vs Peers
Earnings metrics vs comparable public companies
NVO Historical Earnings Data (1990–2025)
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $102.43B | +1.4% | $127.66B | $23.03 | 33.1% | 41.3% |
| 2024 | $100.99B | +20.7% | $128.34B | $22.63 | 34.8% | 44.2% |
| 2023 | $83.68B | +50.7% | $102.57B | $18.62 | 36.0% | 44.2% |
| 2022 | $55.52B | +16.3% | $74.81B | $12.22 | 31.4% | 42.3% |
| 2021 | $47.76B | +13.3% | $58.64B | $10.37 | 33.9% | 41.7% |
| 2020 | $42.14B | +8.2% | $54.13B | $9.01 | 33.2% | 42.6% |
| 2019 | $38.95B | +0.8% | $52.48B | $8.19 | 31.9% | 43.0% |
| 2018 | $38.63B | +1.3% | $47.25B | $7.97 | 34.5% | 42.2% |
| 2017 | $38.13B | +0.5% | $48.97B | $7.70 | 34.1% | 43.8% |
| 2016 | $37.92B | +8.8% | $48.43B | $7.48 | 33.9% | 43.3% |
| 2015 | $34.86B | +31.6% | $49.44B | $6.76 | 32.3% | 45.8% |
| 2014 | $26.48B | +5.2% | $34.49B | $5.04 | 29.8% | 38.8% |
| 2013 | $25.18B | +17.5% | $31.49B | $4.68 | 30.1% | 37.7% |
| 2012 | $21.43B | +25.4% | $29.47B | $3.89 | 27.5% | 37.8% |
| 2011 | $17.10B | +18.7% | $22.37B | $3.00 | 25.8% | 33.7% |
| 2010 | $14.40B | +33.8% | $18.89B | $2.46 | 23.7% | 31.1% |
| 2009 | $10.77B | +11.4% | $14.93B | $1.78 | 21.1% | 29.2% |
| 2008 | $9.67B | +13.2% | $12.40B | $1.55 | 21.2% | 27.2% |
| 2007 | $8.54B | +32.3% | $8.95B | $1.34 | 20.4% | 21.4% |
| 2006 | $6.45B | +10.2% | $9.12B | $1.00 | 16.7% | 23.5% |
| 2005 | $5.86B | +16.0% | $8.08B | $0.89 | 17.4% | 24.0% |
| 2004 | $5.05B | +3.6% | $7.03B | $0.74 | 17.3% | 24.0% |
| 2003 | $4.87B | +19.1% | $6.40B | $0.71 | 18.3% | 24.1% |
| 2002 | $4.09B | +6.2% | $5.97B | $0.59 | 16.3% | 23.7% |
| 2001 | $3.85B | +24.7% | $5.60B | $0.56 | 16.2% | 23.6% |
| 2000 | $3.09B | +27.7% | $4.24B | $0.44 | 14.8% | 20.4% |
| 1999 | $2.42B | +0.2% | $2.92B | $0.34 | 14.7% | 17.8% |
| 1998 | $2.41B | +8.8% | $1.43B | $0.33 | 17.7% | 10.5% |
| 1997 | $2.22B | +23.1% | $2.33B | $0.29 | 13.1% | 13.7% |
| 1996 | $1.80B | +15.4% | $1.98B | $0.24 | 12.1% | 13.3% |
| 1995 | $1.56B | +9.1% | $1.87B | $0.21 | 11.4% | 13.7% |
| 1994 | $1.43B | +0.1% | $1.84B | $0.19 | 10.6% | 13.6% |
| 1993 | $1.43B | +12.4% | $1.94B | $0.19 | 10.9% | 14.8% |
| 1992 | $1.27B | +36.8% | $1.16B | $0.17 | 11.9% | 10.9% |
| 1991 | $930M | +22.4% | $1.40B | $0.16 | 9.5% | 14.3% |
| 1990 | $760M | - | $1.05B | $0.12 | 9.1% | 12.6% |
Download Data
Export NVO earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into NVO consensus models and risk factors.
Should I Buy NVO?
Wall Street verdict, signals, and target summaries.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
36+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NVO — Frequently Asked Questions
Quick answers to the most common questions about buying NVO stock.
What is NVO earnings per share (EPS)?
NVO trailing twelve-month (TTM) diluted EPS is $27.41, reflecting +1.8% year-over-year growth. The 5-year EPS CAGR is +20.6%. Complete EPS history from 1990 to 2025 is available in the table on this page.
What is Novo Nordisk A/S's net income?
Novo Nordisk A/S (NVO) trailing twelve-month net income is $122.0B as of 2025. Earnings grew +1.8% year-over-year. Novo Nordisk A/S has been profitable for 36 consecutive years.
Is NVO profitable?
Yes, NVO is profitable with a TTM net income of $122.0B and a net profit margin of +33.1%. Novo Nordisk A/S has generated profits for 36 consecutive years.
What is NVO's earnings growth rate?
NVO compound annual EPS growth rates (CAGR): 1-Year: +1.8%, 3-Year: +23.5%, 5-Year: +20.6%, 10-Year: +13.0%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1990 to 2025.
What are NVO's profit margins?
Novo Nordisk A/S net profit margin is +33.1%, operating margin is +41.3%, and gross margin is +81.0%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +60.7%.
Is NVO growing earnings?
NVO earnings growth is slowing. Current YoY EPS growth of +1.8% trails the 5-year CAGR of +20.6%. TTM net income is $122.0B.
What was NVO's best earnings year?
Novo Nordisk A/S's highest annual net income on record is $102.4B, achieved in fiscal year 2025. Earnings history on this page spans 1990 to 2025 and includes all annual and quarterly figures.
What were NVO's earnings last quarter?
NVO's most recent reported quarter was Q1 2026. Net income was $48.6B with diluted EPS of $10.91. For a full breakdown of all quarters, see the quarterly earnings table on this page.